Compare Eli Lilly And Co (LLY) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Otis Worldwide Corp — how do they compare? Eli Lilly And Co trades at $1,220.01 (market cap $1.08T), while Otis Worldwide Corp trades at $73.45 (market cap $27.80B). The key difference: Eli Lilly And Co is far larger — about 38.8× Otis Worldwide Corp's market cap, and Otis Worldwide Corp pays the higher dividend (2.41%). Which is the better fit depends on your goals.
| LLY | OTIS | |
|---|---|---|
Market Cap | $1.08T | $27.80B |
Sector | Health | Industrials |
52-Week High | $1.24K | $93.62 |
52-Week Low | $639.43 | $69.34 |
Enterprise Value | $1.13T | $35.84B |
Dividend Yield | 0.57% | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.
Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.
Otis Worldwide (OTIS) trades at $73.82, up 1.3% for the day, with a neutral technical signal. Recent Q2 2026 earnings showed a beat on EPS but included guidance cuts, reflecting margin pressures from labor costs. The company maintains strong service segment growth, with modernization revenue up 24%, though new equipment demand remains weak. Cash flow trends show variability, with 2025 net cash flow negative $1.22 billion due to financing activities, while 2026 projects a positive $146 million.
The investment outlook is mixed; analyst consensus is a Buy with a $92.50 price target, implying significant upside, but risks include persistent margin compression and economic sensitivity. The stock's current valuation below historical averages presents a potential opportunity if service margins stabilize and growth accelerates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
